1. [Pulmonary hypertension in chronic lung diseases]
- Author
-
John G Coghlan, Stefano Ghio, Vincent Cottin, Nazzareno Galiè, Jean-Luc Vachiery, Werner Seeger, Simon Gibbs, Gérald Simonneau, Hunter C. Champion, Athol U. Wells, Teresa De Marco, Marc J. Semigran, Joan Albert Barberà, Yochai Adir, Fernando J. Martinez, Seeger, Werner, Adir, Yochai, Barberà, Joan Albert, Champion, Hunter, Coghlan, John Gerard, Cottin, Vincent, De Marco, Teresa, Galiè, Nazzareno, Ghio, Stefano, Gibbs, Simon, Martinez, Fernando J, Semigran, Marc J, Simonneau, Gerald, Wells, Athol U, Vachiéy, Jean-Luc, University of Giessen and Marburg Lung Center (UGMLC), Max Planck Institute for Heart and Lung Research (MPI-HLR), Max-Planck-Gesellschaft, Israel Institute of Technology, University of Barcelona, University of Pittsburgh Medical Center [Pittsburgh, PA, États-Unis] (UPMC), Royal Free Hospital, Rétrovirus et Pathologie Comparée, Institut National de la Recherche Agronomique (INRA)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Ecole Nationale Vétérinaire de Lyon (ENVL)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS), Hospices Civils de Lyon (HCL), University of California [San Francisco] (UCSF), University of California, Department of Experimental, Diagnostic and Specialty Medicine (DIMES) (DIMES), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Hammersmith Hospital, University of Michigan [Ann Arbor], University of Michigan System, Massachusetts General Hospital, Massachusetts General Hospital [Boston], Hôpital Antoine Béclère, Assistance Publique - Hôpitaux de Paris (AP-HP), Royal Brompton and Harefield NHS Foundation Trust, Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Pfizer, Bayer HealthCare, Bayer Pharma AG, Actelion, Bayer, GlaxoSmithKline, Novartis, Aires Pharmaceuticals, United Therapeutics, Gilead, Werner Seeger, Yochai Adir, Joan Albert Barberà, Hunter Champion, John Gerard Coghlan, Vincent Cottin, Teresa De Marco, Nazzareno Galiè, Stefano Ghio, Simon Gibb, Fernando J. Martinez, Marc J. Semigran, Gerald Simonneau, Athol U. Well, and Jean-Luc Vachiéry
- Subjects
medicine.medical_specialty ,pulmonary hypertension, lung diseases ,Hypertension, Pulmonary ,Pulmonary Fibrosis ,pulmonary hypertension in chronic lung disease ,030204 cardiovascular system & hematology ,[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract ,Pulmonary function testing ,Pulmonary Disease, Chronic Obstructive ,03 medical and health sciences ,FEV1/FVC ratio ,Idiopathic pulmonary fibrosis ,0302 clinical medicine ,Internal medicine ,Animals ,Humans ,Medicine ,COPD ,Lung ,business.industry ,lung fibrosis ,respiratory system ,medicine.disease ,Combined pulmonary fibrosis and emphysema ,Pulmonary hypertension ,exhausted ventilatory reserve ,Obstructive lung disease ,3. Good health ,Surgery ,respiratory tract diseases ,medicine.anatomical_structure ,030228 respiratory system ,Chronic Disease ,Cardiology ,Lung Diseases, Interstitial ,Cardiology and Cardiovascular Medicine ,business ,exhausted circulatory reserve ,combined pulmonary fibrosis and emphysema - Abstract
International audience; Chronic obstructive lung disease (COPD) and diffuse parenchymal lung diseases (DPLD), including idiopathic pulmonary fibrosis (IPF) and sarcoidosis, are associated with a high incidence of pulmonary hypertension (PH), which is linked with exercise limitation and a worse prognosis. Patients with combined pulmonary fibrosis and emphysema (CPFE) are particularly prone to the development of PH. Echocardiography and right heart catheterization are the principal modalities for the diagnosis of COPD and DPLD. For discrimination between group 1 PH patients with concomitant respiratory abnormalities and group 3 PH patients (PH caused by lung disease), patients should be transferred to a center with expertise in both PH and lung diseases for comprehensive evaluation. The task force encompassing the authors of this article provided criteria for this discrimination and suggested using the following definitions for group 3 patients, as exemplified for COPD, IPF, and CPFE: COPD/IPF/CPFE without PH (mean pulmonary artery pressure [mPAP] = 25 mm Hg); PH-COPD, PH-IPF, and PH-CPFE); COPD/IPF/CPFE with severe PH (mPAP >= 35 mm Hg or mPAP >= 25 mm Hg with low cardiac index [CI
- Published
- 2014
- Full Text
- View/download PDF